



Perceptronix
Early diagnosis, better outcomes™

PRESS RELEASE
For immediate release

PERCEPTRONIX FEATURED AT BIOPARTNERING NORTH AMERICA

VANCOUVER, BC (February 1, 2008) – Perceptronix Medical Inc. (Perceptronix) is pleased to announce its participation at the 6th Annual BioPartnering North America conference, February 3-5, 2008 at the Westin Bayshore in Vancouver, BC. Not only will Perceptronix be represented on the exhibiting floor (Monday, February 4th, 9:45 – 11:45 am) but Dr. Bojana Turic will also highlight Perceptronix' recent developments during her presentation at 3:30 pm the same day.

“We are pleased to be a part of BioPartnering North America,” commented Bojana Turic, President and CEO. “We are always looking for opportunities to showcase Perceptronix' highly innovative auto-fluorescence and functional imaging endoscopy technology and early cancer detection laboratory services. BPN is an excellent venue to develop new relationships and identify partnering prospects.”

Now in its sixth year, BioPartnering North America (BPN) offers excellent partnering opportunities for lifescience innovators and investors. Co-hosted by LifeSciences British Columbia, BIOTECCanada, and BioAlberta, BPN annually attracts senior business development executives from around the globe. BPN offers a targeted approach to the best lifescience partnering opportunities.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix Medical Inc. (founded in 1999) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency, a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

Perceptronix is focused on offering quantitative image cell analysis services for early cancer detection. Perceptronix' products and services offer an improvement over existing detection and localization technologies and provide physicians with increased options for prolonging and improving the quality of patients' lives.

This news release is not, and under no circumstances, to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Media Contact:

Amanda Smith, BSc
Smith Biotech
Phone: (778) 846-4116
amanda@smithbiotech.com